[go: up one dir, main page]

AR056879A1 - Antagonistas del receptor 3 de la histamina - Google Patents

Antagonistas del receptor 3 de la histamina

Info

Publication number
AR056879A1
AR056879A1 ARP060104658A ARP060104658A AR056879A1 AR 056879 A1 AR056879 A1 AR 056879A1 AR P060104658 A ARP060104658 A AR P060104658A AR P060104658 A ARP060104658 A AR P060104658A AR 056879 A1 AR056879 A1 AR 056879A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
alkyls
group
halogens
Prior art date
Application number
ARP060104658A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR056879A1 publication Critical patent/AR056879A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/58—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Una composicion farmacéutica que contiene el compuesto de formula (1), para tratar un trastorno o enfermedad seleccionado del grupo que consiste en depresion, trastornos del humor, esquizofrenia, trastornos de ansiedad, enfermedad de Alzheimer, trastorno de hiperactividad con déficit de atencion (ADHD), trastornos psicoticos, trastornos cognitivos, trastornos del sueno, obesidad, vértigo, epilepsia, mareo, enfermedades respiratorias, alergias, reacciones de las vías respiratorias inducidas por alergia, rinitis alérgica, congestion nasal, congestion alérgica, congestion, hipotension, dolencias cardiovasculares, enfermedades del tracto gastrointestinal, hiper e hipo motilidad y secrecion ácida del tracto gastrointestinal. Reivindicacion 1: Un compuesto de formula (1), o una de sus sales farmacéuticamente aceptables, en la que R1 y R2 se seleccionan independientemente cada uno del grupo que consiste en hidrogeno; alquilo C1-8 opcionalmente sustituido con de 1 a 4 halogenos; un grupo alquilo C1-4 opcionalmente sustituido con un sustituyente seleccionado del grupo que consiste en OH, de uno a cuatro alquilos C1-4, cicloalquilo C3-7, dialquilamino C1-4, arilo C6-14 opcionalmente sustituido con un halogeno y opcionalmente sustituido con ariloxi C6-10 opcionalmente sustituido con de uno a dos halogenos, y heteroarilo de 5-10 miembros opcionalmente sustituido con un grupo arilo C6-10 y opcionalmente sustituido con de uno a tres grupos alquilo C2-4; cicloalquilo C3-7; arilo C6-14; -alquil C0-3-O-alquilo C1-3 opcionalmente sustituido con alquilo C1-3; -alquil C1-3-C(=O)O-alquilo C1-3; heterocicloalquilo de 3-8 miembros opcionalmente sustituido con uno o más grupos alquil-carbonilo C1-4; arilsulfonilo C6-19 opcionalmente sustituido con uno o más alquilos C1-2; heteroarilo de 5-10 miembros; y aril C6-14-alquilen C0-4-O-alquilo C0-4, en el que cada alquilo C0-4 y cada alquileno C0-4 están opcionalmente sustituidos con de uno a cuatro alquilos C1-4; u opcionalmente R1 y R2, junto con el nitrogeno al que están unidos, forman un anillo alifático saturado o insaturado de 4, 5, 6, o 7 miembros, en el que uno de los carbonos en dicho anillo alifático está opcionalmente reemplazado por O, S, NR3, o CO, y en el que dicho anillo está opcionalmente fusionado a un arileno C6-10 y está opcionalmente sustituido en un carbono del anillo con un sustituyente seleccionado del grupo que consiste en -OH, heteroarilo de 5-10 miembros opcionalmente sustituido con uno o más halogenos y opcionalmente sustituido con uno o más alquilos C1-2, alcoxi C1-4 opcionalmente sustituido con uno o más alcoxi C1-2 y opcionalmente sustituido con uno o más dialquilaminocarbonilos C1-4, y uno o dos alquilos C1-4 opcionalmente e independientemente sustituidos con uno o más alcoxi C1-2; en la que R3 es hidrogeno; alquilo C1-8 opcionalmente sustituido con de 1 a 4 halogenos; heteroarilo de 5-10 miembros opcionalmente sustituido con un sustituyente seleccionado del grupo que consiste en halogeno, alquilo C1-4, alcoxi C1-2, arilo C5-10, alquilaminocarbonilo C1-4, y ciano; un grupo alquilo C1-4 opcionalmente sustituido con un sustituyente seleccionado del grupo que consiste en alcoxicarbonilo C1-2, heteroarilo de 5-10 miembros opcionalmente sustituido con uno o más alquilos C1-2, de uno a cuatro alquilos C1-4, cicloalquilo C3-7, y arilo C6-14; arilo C6-10 opcionalmente sustituido con uno o dos alquilos C1-2; aIquilcarbonilo C1-4; o aril C6-14-alquilen C0-4-O-alquilo C0-4, en el que cada alquilo C0-4 y cada alquileno C0-4 están opcionalmente sustituidos con de uno a cuatro alquilos; R4 se selecciona independientemente del grupo que consiste en hidrogeno, alquilo C1-4, alcoxilo C1-4, halogeno, nitrilo, -SO2-alquilo C1-4, -SO2NH-alquilo C1-4, y -C(=O)NH-alquilo C1-4; n es 0, 1, 2, 3 o 4; R5 es OH, -O-alquilo C1-3, halogeno o hidrogeno; R6 es hidrogeno, alquilo C1-4 opcionalmente sustituido con de 1 a 4 halogenos, o cicloalquil C3-7-alquilo C0-4; R7 es hidrogeno, alquilo C1-8 opcionalmente sustituido con de 1 a 4 halogenos, o cicloalquil C3-7-alquilo C0-4, en el que cada alquilo C0-4 está opcionalmente sustituido con de uno a cuatro alquilo C1-4 y; R8 es hidrogeno, alquilo C1-8 opcionalmente sustituido con de 1 a 4 halogenos, o cicloalquil C3-7-alquilo C0-4; u opcionalmente R7 y R8, junto con el nitrogeno al que están unidos, forman un anillo heterocíclico de 4, 5, 6, o 7 miembros, en el que dicho anillo heterocíclico está opcionalmente sustituido con uno o dos alquilos C1-4 y en el que uno de los carbonos de dicho anillo heterocíclico que está separado de dicho nitrogeno en dicho anillo heterocíclico por al menos dos átomos, está opcionalmente reemplazado por O, S, NR9, o C=O, en el que R9 es hidrogeno, alquilo C1-8 opcionalmente sustituido con de 1 a 4 halogenos, o cicloalquil C3-7-alquilo C0-4, y en el que cada alquilo C0-4 está opcionalmente sustituido con de uno a cuatro alquilos C1-4.
ARP060104658A 2005-10-27 2006-10-25 Antagonistas del receptor 3 de la histamina AR056879A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73099605P 2005-10-27 2005-10-27

Publications (1)

Publication Number Publication Date
AR056879A1 true AR056879A1 (es) 2007-10-31

Family

ID=37776539

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104658A AR056879A1 (es) 2005-10-27 2006-10-25 Antagonistas del receptor 3 de la histamina

Country Status (39)

Country Link
US (2) US8158673B2 (es)
EP (1) EP1951660B1 (es)
JP (2) JP4319245B2 (es)
KR (1) KR101025358B1 (es)
CN (1) CN101296898B (es)
AP (1) AP2403A (es)
AR (1) AR056879A1 (es)
AU (1) AU2006307645B2 (es)
BR (1) BRPI0617797A2 (es)
CA (1) CA2621323C (es)
CR (1) CR9910A (es)
CU (1) CU23806B7 (es)
DK (1) DK1951660T3 (es)
DO (1) DOP2006000239A (es)
EA (1) EA013602B1 (es)
EC (1) ECSP088373A (es)
ES (1) ES2444370T3 (es)
GE (1) GEP20104937B (es)
GT (1) GT200600471A (es)
HN (1) HN2006036385A (es)
HR (1) HRP20140061T1 (es)
IL (1) IL189866A (es)
MA (1) MA29888B1 (es)
MY (1) MY145001A (es)
NI (1) NI200800132A (es)
NL (1) NL1032713C2 (es)
NO (1) NO20082264L (es)
NZ (1) NZ566488A (es)
PE (1) PE20070720A1 (es)
PL (1) PL1951660T3 (es)
PT (1) PT1951660E (es)
RS (2) RS53153B (es)
SI (1) SI1951660T1 (es)
TN (1) TNSN08150A1 (es)
TW (1) TWI318206B (es)
UA (1) UA88719C2 (es)
UY (1) UY29882A1 (es)
WO (1) WO2007049123A1 (es)
ZA (1) ZA200803130B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158673B2 (en) * 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
AU2008208653B2 (en) * 2007-01-22 2012-11-22 Pfizer Products Inc. Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof
JP5497429B2 (ja) 2007-03-07 2014-05-21 武田薬品工業株式会社 ベンゾオキサゼピン誘導体およびその用途
WO2009024823A2 (en) 2007-08-22 2009-02-26 Astrazeneca Ab Oxadiazole derivatives as dgat inhibitors
CN101939306A (zh) * 2007-12-07 2011-01-05 美国辉瑞有限公司 反式-n-异丁基-3-氟-3-[3-氟-4-(吡咯烷-1-基-甲基)-苯基]环丁烷甲酰胺的甲苯磺酸盐
US8691804B2 (en) 2008-05-08 2014-04-08 Evotec Ag Azetidines and cyclobutanes as histamine H3 receptor antagonists
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
MX2012009473A (es) 2010-02-18 2012-09-12 Astrazeneca Ab Procesos para preparar derivados de ciclopropilamidas e intermedios asociados con estas.
ES2602794T3 (es) 2011-03-31 2017-02-22 Pfizer Inc Piridinonas bicíclicas novedosas
WO2012172449A1 (en) 2011-06-13 2012-12-20 Pfizer Inc. Lactams as beta secretase inhibitors
EP2751116B1 (en) 2011-08-31 2016-10-12 Pfizer Inc Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
CA2872154C (en) 2012-05-04 2016-08-23 Pfizer Inc. Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin-2-amine compounds as inhibitors of app, bace1 and bace2
CN105732639A (zh) 2012-06-29 2016-07-06 辉瑞大药厂 作为LRRK2抑制剂的4-(取代的氨基)-7H-吡咯并〔2,3-d〕嘧啶类
US9260455B2 (en) 2012-09-20 2016-02-16 Pfizer Inc. Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
EP2931731A1 (en) 2012-12-11 2015-10-21 Pfizer Inc. Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
US9403846B2 (en) 2012-12-19 2016-08-02 Pfizer Inc. Carbocyclic- and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
CA2897678A1 (en) 2013-02-13 2014-08-21 Pfizer Inc. Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
MA38333A1 (fr) 2013-02-19 2017-02-28 Pfizer Composés d'azabenzimidazole en tant qu'inhibiteurs d'isozymes pde4 pour le traitement de troubles du snc et d'autres affections
EP3052495B1 (en) 2013-10-04 2019-06-26 Pfizer Inc Novel bicyclic pyridinones as gamma-secretase modulators
US9695171B2 (en) 2013-12-17 2017-07-04 Pfizer Inc. 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
CN106211770B (zh) 2014-04-01 2018-02-06 辉瑞公司 作为γ‑分泌酶调节剂的色烯和1,1A,2,7B‑四氢环丙烷并[c]色烯吡啶并吡嗪二酮
CN106459088A (zh) 2014-04-10 2017-02-22 辉瑞公司 2‑氨基‑6‑甲基‑4，4a，5，6‑四氢吡喃并[3，4‑d][1，3]噻嗪‑8a(8H)‑基‑1，3‑噻唑‑4‑基酰胺
WO2016012896A1 (en) 2014-07-24 2016-01-28 Pfizer Inc. Pyrazolopyrimidine compounds
SG11201700243YA (en) 2014-08-06 2017-02-27 Pfizer Imidazopyridazine compounds
BR112017015693A2 (pt) 2015-02-03 2018-03-20 Pfizer ciclopropabenzofuranil piridopirazinadionas
DK3310784T3 (da) 2015-06-17 2020-11-09 Pfizer Tricykliske forbindelser og deres anvendelse som phosphodiesterasehæmmere
AU2016322813B2 (en) 2015-09-14 2021-04-01 Pfizer Inc. Novel imidazo (4,5-c) quinoline and imidazo (4,5-c)(1,5) naphthyridine derivatives as LRRK2 inhibitors
WO2017051294A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides useful as bace inhibitors
WO2017051303A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors
EP3353183A1 (en) 2015-09-24 2018-08-01 Pfizer Inc N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3]thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl]amides
MX379704B (es) 2016-02-23 2025-03-11 Pfizer Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida
SG11201811712QA (en) 2016-07-01 2019-01-30 Pfizer 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases
SG11201908322WA (en) 2017-03-10 2019-10-30 Pfizer Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors
US11161844B2 (en) 2017-03-10 2021-11-02 Pfizer Inc. Cyclic substituted imidazo[4,5-c]quinoline derivatives
US20230137562A1 (en) 2017-06-07 2023-05-04 Adrx, Inc. Tau aggregation inhibitors
PT3642202T (pt) 2017-06-22 2023-02-02 Pfizer Derivados de dihidro-pirrolo-piridina
AU2018318319A1 (en) 2017-08-18 2020-02-20 Adrx, Inc. Tau aggregation peptide inhibitors
CA3094366A1 (en) 2018-03-23 2019-09-26 Pfizer Inc. Piperazine azaspiro derivatives
WO2022182658A1 (en) 2021-02-23 2022-09-01 Hoth Therapeutics, Inc. Use of aprepitant for treating alzheimer's disease
CN116514645A (zh) * 2023-04-08 2023-08-01 绍兴上虞华伦化工有限公司 二氟-4溴苯甲醛及其制备工艺
WO2025145091A1 (en) 2023-12-29 2025-07-03 Pfizer Inc. Crystalline forms of a muscarinic m4 receptor modulator and methods of treating diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6559140B2 (en) 2000-03-09 2003-05-06 Abbott Laboratories Cyclic and bicyclic diamino histamine-3 receptor antagonists
JP2004532834A (ja) 2001-03-23 2004-10-28 イーライ・リリー・アンド・カンパニー ヒスタミンｈ３受容体アンタゴニストである非イミダゾール系アリールアルキルアミン化合物、その製造および治療的使用
US7671047B2 (en) 2002-06-19 2010-03-02 Sanofi-Aventis Deutschland Gmbh Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
JP2004131497A (ja) * 2002-09-18 2004-04-30 Satoshi Shuto シスシクロプロパン誘導体
AU2004259263B2 (en) * 2003-07-29 2010-12-16 High Point Pharmaceuticals, Llc Pyridazinyl- piperazines and their use as histamine H3 receptor ligands
EP1669350B1 (en) * 2003-09-22 2012-02-29 Msd K.K. Piperidine derivatives
BRPI0507374A (pt) 2004-02-02 2007-07-10 Pfizer Prod Inc moduladores do receptor de histamina-3
JP4777974B2 (ja) * 2004-04-01 2011-09-21 イーライ リリー アンド カンパニー ヒスタミンｈ３受容体作用物質、製剤および治療的使用
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
CA2607499C (en) 2005-06-22 2010-11-30 Pfizer Products Inc. Histamine-3 receptor antagonists
US8158673B2 (en) * 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
AU2008208653B2 (en) * 2007-01-22 2012-11-22 Pfizer Products Inc. Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
RS20080173A (sr) 2009-07-15
EA200800946A1 (ru) 2008-10-30
EP1951660A1 (en) 2008-08-06
ECSP088373A (es) 2008-05-30
BRPI0617797A2 (pt) 2011-08-09
GEP20104937B (en) 2010-03-25
IL189866A0 (en) 2008-11-03
AP2403A (en) 2012-05-04
IL189866A (en) 2012-06-28
NZ566488A (en) 2011-07-29
JP5064427B2 (ja) 2012-10-31
JP2009513619A (ja) 2009-04-02
ES2444370T3 (es) 2014-02-24
NO20082264L (no) 2008-07-22
TW200800886A (en) 2008-01-01
US8158673B2 (en) 2012-04-17
JP2009161554A (ja) 2009-07-23
CU23806B7 (es) 2012-04-15
UA88719C2 (ru) 2009-11-10
DOP2006000239A (es) 2007-04-30
DK1951660T3 (da) 2014-01-27
SI1951660T1 (sl) 2014-02-28
MY145001A (en) 2011-12-15
TNSN08150A1 (fr) 2009-10-30
HK1124831A1 (en) 2009-07-24
HRP20140061T1 (hr) 2014-02-14
US20120220568A1 (en) 2012-08-30
JP4319245B2 (ja) 2009-08-26
CN101296898A (zh) 2008-10-29
CN101296898B (zh) 2013-07-24
PE20070720A1 (es) 2007-08-11
CA2621323A1 (en) 2007-05-03
TWI318206B (en) 2009-12-11
KR101025358B1 (ko) 2011-03-28
PL1951660T3 (pl) 2014-04-30
CR9910A (es) 2008-05-16
HN2006036385A (es) 2009-10-30
UY29882A1 (es) 2007-05-31
NL1032713C2 (nl) 2007-10-09
GT200600471A (es) 2007-06-08
AP2008004401A0 (en) 2008-04-30
AU2006307645B2 (en) 2012-02-16
ZA200803130B (en) 2009-01-28
US8389743B2 (en) 2013-03-05
EA013602B1 (ru) 2010-06-30
CA2621323C (en) 2010-08-24
CU20080069A7 (es) 2009-12-17
NI200800132A (es) 2010-02-15
NL1032713A1 (nl) 2007-05-01
MA29888B1 (fr) 2008-10-03
WO2007049123A1 (en) 2007-05-03
US20080096955A1 (en) 2008-04-24
EP1951660B1 (en) 2013-12-11
PT1951660E (pt) 2014-02-10
AU2006307645A1 (en) 2007-05-03
RS53153B (sr) 2014-06-30
KR20080054413A (ko) 2008-06-17

Similar Documents

Publication Publication Date Title
AR056879A1 (es) Antagonistas del receptor 3 de la histamina
PE20120031A1 (es) Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1
AR060318A1 (es) Isoindolonas potenciadoras de receptores metabotropicos de glutamato, composiciones farmaceuticas que las comprenden y el uso de las mismas en la fabricacion de un medicamento para el tratamiento de trastornos neurologicos y psiquiatricos.
CO6210771A2 (es) Moduladores 2-aminopirimidina del receptor de histamina h4
AR074358A1 (es) Derivados de pirazina como inhibidores de la fosfodiesterasa 10
AR060658A1 (es) Derivados de diceto-piperazina y piperidina como agentes antivirales
AR057104A1 (es) Diaminopirimidinas como moduladores de p2 x3 y p2x2 /3 y composicion farmaceutica
AR068014A1 (es) Derivados de pirimidin-2-il-amina, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la cinasa.
TW201311660A (zh) 治療性化合物及相關使用方法
AR047056A1 (es) Derivados de pirimidinas condensadas. composiciones farmacéuticas
AR054035A1 (es) Derivados benzodioxano y benzodioxolano y uso de los mismos
PE20130279A1 (es) Compuestos heteroarilo nitrogenados
AR064874A1 (es) Derivados de hexahidro y tetrahidropterinas,composiciones farmaceuticas que los contienen y usos de las mismas en trastornos cardiovasculares y psiquiatricos entre otros
AR065718A1 (es) Compuestos heterociclicos nitrogenados,utiles en el diagnostico y tratamiento de trastornos hiperproliferativos.
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
AR077267A1 (es) Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes.
AR058984A1 (es) Derivados de ciclohexil piperazinil metanona
AR037489A1 (es) Quinolinas sustituidas y proceso para su preparacion
PE20071156A1 (es) COMPUESTOS DERIVADOS DE 4,5,6,7-TETRAHIDRO-1H-INDAZOL COMO POTENCIADORES DEL RECEPTOR DEL ACIDO a-AMINO-3-HIDROXI-5-METILISOXAZOL-4-PROPIONICO (AMPA)
AR040626A1 (es) Derivados de quinolina utiles como ligandos del receptor del neuropeptido y (npy)
CO6260069A2 (es) Tiazolopiridin-2-iloxi-fenil y tiazolopirazin-2-iloxi-fenil aminas como moduladores de la leucotrieno a4 hidrolasa
PE20091444A1 (es) Derivados de isoxazolo-pirazina
AR067772A1 (es) Derivados piperazinicos de nicotinamida, medicamentos que los contienen, proceso para prepararlos y usos de los mismos para el tratamiento de trastornos asociados al sistema nervioso, cardiovascular y/o trastornos metabolicos.
AR078756A1 (es) Moduladores alostericos positivos (map)
AR063226A1 (es) Bifenilsulfonilos y fenil heteroaril sulfonilos como moduladores del receptor h3 de histamina, su uso en medicamentos para el tratamiento de los trastornos relacionados con dicho receptor y una composicion farmaceutica que los comprende.

Legal Events

Date Code Title Description
FG Grant, registration